The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1696
February 19, 2024
View Complete Issue         Table of Contents 2019 
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
February 19, 2024 (Issue: 1696)
Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent surgical/invasive procedure. It is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Balfaxar: Another Four-Factor PCC for Warfarin Reversal
Article code: 1696d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.